Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 4NIH 2NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Stomach Neoplasms 1

Interventions

pembrolizumab 131Carboplatin 106Paclitaxel 66Cisplatin 61Gemcitabine 57Pemetrexed 56Bevacizumab 50Docetaxel 47Fluorouracil 40Oxaliplatin 38Dexamethasone 34130-nm albumin-bound paclitaxel 34Leucovorin 33atezolizumab 32Cetuximab 32durvalumab 30Nivolumab 28Rituximab 26Cyclophosphamide 26Capecitabine 26Prednisone 25Fulvestrant 24enzalutamide 23Lenalidomide 22venetoclax 21Letrozole 20Irinotecan 20Doxorubicin 17ribociclib 16pomalidomide 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Ramucirumab × 30 days × Clear all
NCT05062980 2026-06-03

Acclaim-2

Genprex, Inc.

Phase 1 Terminated
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Recruiting
398 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Daiichi Sankyo

Phase 3 Active not recruiting
490 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT07098338 2026-05-27

LIBRA

AstraZeneca

Phase 2 Recruiting
278 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡